Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review

Author(s): Jesus Rodriguez-Pascual*, Antonio Cubillo

Journal Name: Current Pharmacogenomics and Personalized Medicine
Formerly Current Pharmacogenomics

Volume 15 , Issue 2 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.

Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 21 February, 2018
Page: [81 - 85]
Pages: 5
DOI: 10.2174/1875692115666170815161754

Article Metrics

PDF: 28